Cell-Based Immunotherapy
Center for Stem Cell and Translational Immunotherapy — Harvard Medical School · Harvard Stem Cell Institute
Featured Research & Media
- Gene-edited and engineered stem cell platform drives immunotherapy for brain metastatic melanomas
Science Translational Medicine, 2023 - Bifunctional cancer cell–based vaccine concomitantly drives direct tumor killing and antitumor immunity
Science Translational Medicine, 2023 - Treating cancer with re-purposed cancer cells
TEDxBoston talk by Dr. Khalid Shah - The potential of the gut microbiome to reshape the cancer therapy paradigm
JAMA Oncology, 2022 - An inducible RIPK3-driven necroptotic system enhances cancer cell-based immunotherapy and ensures safety
The Journal of Clinical Investigation, 2024 - Anti-tumor immunity mediated by engineered allogeneic stem cells exploiting TRAIL-induced cell death and FLT3L immunomodulation
Clinical Cancer Research, 2025
About Us
Cell-based immunotherapy for cancer has produced promising results. The overall mission of CSTI, led by Dr. Khalid Shah is to develop and test novel targeted cell-based immunotherapies for cancer. CSTI capitalizes on the unique expertise in interdisciplinary research spanning the biology of different cell types, gene editing/engineering and cell signaling, as well as our proven abilities to synthesize new insights from disparate fields, to lead interdisciplinary teams into new territory.
140+
Papers
161
Alumni
49
Nationalities
The Latest News
- Using gene-edited stem cells and oncolytic viruses to treat lung cancer brain metastases
JNCCN360, 2025 - New dual stem cell therapy developed to treat brain metastasis in non‑small cell lung cancer
Medical Xpress, 2025 - Un enfoque dual para el cáncer: seguridad y respuesta inmunitaria mejoradas con RIPK3
Gaceta Médica, 2025 - To combat cancer treatment resistance, researchers try leveraging evolution
National Cancer Institute, 2024 - Meet the Faculty: Dr. Khalid Shah
SACT / TMC, 2024
Center for Stem Cell and Translational Immunotherapy (CSTI) 